U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H23F3O5S.C6H14N2O2
Molecular Weight 590.652
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SELADELPAR LYSINE ANHYDROUS

SMILES

NCCCC[C@H](N)C(O)=O.CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC=C(OCC(O)=O)C(C)=C2

InChI

InChIKey=IOIAOZMQFNHRKR-FFHLUDTASA-N
InChI=1S/C21H23F3O5S.C6H14N2O2/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26;7-4-2-1-3-5(8)6(9)10/h4-10,17H,3,11-13H2,1-2H3,(H,25,26);5H,1-4,7-8H2,(H,9,10)/t17-;5-/m10/s1

HIDE SMILES / InChI
Molecular Formula C6H14N2O2
Molecular Weight 146.1876
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula C21H23F3O5S
Molecular Weight 444.465
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

MBX-8025 (Seladelpar) is an agonist of peroxisome proliferator-activated receptor delta. MBX-8025 improves insulin sensitivity and reverses dyslipidemia and hepatic storage of lipotoxic lipids to improve nonalcoholic steatohepatitis pathology in atherogenic diet-fed obese diabetic mice. MBX-8025 improves lipoprotein subfractions associated with atherogenic dyslipidemia. CymaBay Therapeutics is developing MBX-8025 for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis and nonalcoholic steatohepatitis.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Peroxisome proliferator-activated receptor delta
29
Target ID: Q03181|||Q9BUD4
Gene ID: 5467.0
Gene Symbol: PPARD
Target Organism: Homo sapiens (Human)
Agonist
2678
 2.0 nM [EC50]
PubMed

PubMed

TitleDatePubMed
MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin.
2011 Sep

Sample Use Guides

In Vivo Use Guide
Phase 2 study to evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 52 weeks of treatment
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:51:03 GMT 2023
Edited
by admin
on Fri Dec 15 15:51:03 GMT 2023
Record UNII
75US2513Z8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SELADELPAR LYSINE ANHYDROUS
Common Name English
MBX-8025 LYSINE ANHYDROUS
Code English
ACETIC ACID, (4-(((2R)-2-ETHOXY-3-(4-(TRIFLUOROMETHYL)PHENOXY)PROPYL)THIO)-2-METHYLPHENOXY)-, COMPD. WITH L-LYSINE (1:1)
Systematic Name English
Code System Code Type Description
SMS_ID
100000177202
Created by admin on Fri Dec 15 15:51:03 GMT 2023 , Edited by admin on Fri Dec 15 15:51:03 GMT 2023
PRIMARY
FDA UNII
75US2513Z8
Created by admin on Fri Dec 15 15:51:03 GMT 2023 , Edited by admin on Fri Dec 15 15:51:03 GMT 2023
PRIMARY
PUBCHEM
15983987
Created by admin on Fri Dec 15 15:51:03 GMT 2023 , Edited by admin on Fri Dec 15 15:51:03 GMT 2023
PRIMARY
CAS
928821-41-4
Created by admin on Fri Dec 15 15:51:03 GMT 2023 , Edited by admin on Fri Dec 15 15:51:03 GMT 2023
PRIMARY
Related Record Type Details
Structure of SELADELPAR
PARENT -> SALT/SOLVATE
Structure of SELADELPAR LYSINE
SOLVATE->ANHYDROUS
Related Record Type Details
Structure of SELADELPAR
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966